Rein Therapeutics (RNTX) Financials: Revenue & Earnings
RNTX$0.68-0.03 -3.95%
$58.35M
Market Cap
—
P/E
—
Forward P/E
70
Score
Rein Therapeutics (RNTX) Financials: Revenue & Earnings
RNTX price $0.68 -0.03 -3.95%
- Ticker
- RNTX
- Price
- $0.68
- Change
- -0.03 -3.95%
- Market cap ?
- $58.35M
- Beta ?
- 1.35
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 70
- Value
- 59
- Quality
- 51
- Growth
- 100
Stocklytics score rationale: value 59, quality 51, growth 100.
Fair value
RNTX fair value Not meaningful. Price $0.68.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-13 | — | -0.10 | — | — |
| 2026-08-14 | -0.10 | -0.17 | — | — |
| 2026-05-15 | -0.19 | -0.49 | — | — |
| 2026-03-26 | -1.09 | -1.09 | — | — |
| 2025-11-14 | -0.21 | -0.24 | — | — |
| 2025-08-14 | -0.28 | -0.22 | — | — |
| 2025-04-07 | -0.26 | -0.14 | — | — |
| 2024-12-31 | -1.89 | -0.46 | — | — |
| 2024-11-14 | -0.27 | -0.25 | — | — |
| 2024-08-14 | -0.45 | -0.25 | — | — |
| 2024-05-15 | -0.86 | -0.14 | — | — |
| 2023-12-31 | -1.54 | -0.16 | — | — |
| 2023-09-30 | -0.40 | -0.20 | — | — |
| 2023-08-11 | -0.39 | -0.40 | — | — |
| 2023-05-08 | — | -0.60 | — | — |
| 2023-03-20 | — | -1.30 | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-27 | VON RICKENBACH JOSEF H | Buy | 4.50K | $1.07 | 4.82K |
| 2026-05-26 | VON RICKENBACH JOSEF H | Buy | 23.19K | $1.06 | 24.47K |
| 2026-05-22 | VON RICKENBACH JOSEF H | Buy | 15.95K | $1.05 | 16.71K |
| 2026-05-21 | VON RICKENBACH JOSEF H | Buy | 3.42K | $1.04 | 3.56K |
| 2026-05-08 | WINDSOR JAMES BRIAN | Sell | 150.00K | $1.17 | 175.50K |
| 2026-04-30 | WINDSOR JAMES BRIAN | Buy | 25.00K | $1.00 | 25.00K |
| 2025-11-14 | Voss Capital, LP | Buy | 104.18K | $1.22 | 127.59K |
| 2025-10-28 | Voss Capital, LP | Buy | 178.39K | $1.39 | 247.96K |
| 2025-10-27 | Voss Capital, LP | Buy | 92.64K | $1.37 | 126.92K |
| 2025-10-27 | Voss Capital, LP | Buy | 4.84K | $1.37 | 6.62K |
| 2025-10-24 | Voss Capital, LP | Buy | 30.18K | $1.39 | 41.96K |
| 2025-09-24 | Voss Capital, LP | Other | 0 | — | — |
| 2025-09-24 | Voss Capital, LP | Other | 0 | — | — |
| 2025-07-23 | Aivado Manuel | Buy | 17.50K | $1.55 | 27.12K |
| 2025-07-23 | VON RICKENBACH JOSEF H | Buy | 17.50K | $1.55 | 27.12K |
| 2025-07-23 | Musso Alan A | Buy | 17.50K | $1.55 | 27.12K |
| 2025-07-23 | Fairey William | Buy | 17.50K | $1.55 | 27.12K |
| 2025-07-23 | Ambros Reinhard J. | Buy | 17.50K | $1.55 | 27.12K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 59, holders +14 vs prior quarter. Ownership 134.55%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| VOSS CAPITAL, LP | 5.26M | 873.56K | +19.91% | 5.47M |
| CABLE CAR CAPITAL, LP | 5.20M | 4.78M | +1136.90% | 5.40M |
| ADAR1 CAPITAL MANAGEMENT, LLC | 4.50M | 4.50M | New | 4.68M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.38M | 2.38M | +238.29% | 3.51M |
| BIOS CAPITAL MANAGEMENT, LP | 2.98M | 1.00M | +50.44% | 3.10M |
| IKARIAN CAPITAL, LLC | 2.95M | 2.95M | New | 3.07M |
| GREAT POINT PARTNERS LLC | 2.58M | 2.58M | New | 2.68M |
| CITADEL ADVISORS LLC | 2.44M | 2.44M | New | 2.54M |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | 1.70M | 1.70M | New | 1.77M |
| SENVEST MANAGEMENT, LLC | 1.23M | 1.00M | +433.10% | 1.28M |
| PROSIGHT MANAGEMENT, LP | 1.10M | 688.40K | +167.25% | 1.14M |
| BLEICHROEDER LP | 1.00M | 1.00M | New | 1.04M |
| BOOTHBAY FUND MANAGEMENT, LLC | 889.45K | 889.45K | New | 925.03K |
| GEODE CAPITAL MANAGEMENT, LLC | 733.14K | 388.45K | +112.70% | 762.54K |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 511.61K | 0 | 0.00% | 532.07K |
| VANGUARD FIDUCIARY TRUST CO | 382.51K | 228.00K | +147.56% | 397.82K |
| STATE STREET CORP | 379.60K | 303.70K | +400.11% | 394.79K |
| EMPERY ASSET MANAGEMENT, LP | 370.83K | 370.83K | New | 385.67K |
| SIGMA PLANNING CORP | 353.68K | 5.00K | +1.43% | 367.82K |
| BLACKROCK, INC. | 326.20K | 257.68K | +376.02% | 339.25K |
| TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 300.76K | 27.13K | +9.92% | 312.79K |
| SEQUOIA FINANCIAL ADVISORS, LLC | 250.00K | 250.00K | New | 260.00K |
| GAGNON SECURITIES LLC | 229.07K | -10.45K | -4.36% | 238.23K |
| STONEPINE CAPITAL MANAGEMENT, LLC | 218.04K | 218.04K | New | 226.76K |
| PALOGIC VALUE MANAGEMENT, L.P. | 180.00K | 0 | 0.00% | 187.20K |
Earnings and financials
Rein Therapeutics Inc. (RNTX) trades at $0.68, with a market cap of $58.35M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn